Refined whooping cough vaccine provides long-term boost

by Kerry Faulkner
Refined whooping cough vaccine provides long-term boost
“Five to nine year-old children and 10 to 14 year-old adolescents are the biggest carriers and potential transmitters of infections to infants so that’s where our focus is at present,” Prof Mukkur says. Credit: Sanofi Pasteur

Perth researchers developing a new whooping cough vaccine have described immune responses produced in pre-clinical testing with the new vaccine as 'exquisite'.

Curtin University School of Biomedical Sciences lead researcher Associate Professor Trilochan Mukkur says research reached an important milestone recently with the new vaccine showing suitability for use in people who have already been inoculated.

"Pre-clinical modelling shows vaccinated subjects can skew their immune responses to those types likely to provide longer-term protection," he says.

Prof Mukkur says clinical trials are expected to start within the next two to three years and the product should be on the market in the next five to eight years.

He says the new vaccine will have a number of advantages over the old one.

These advantages include that it would be administered by nasal spray, eliminating the distress, particularly in very young children and adolescents, of having a needle and swelling at the injection point that occurs in 20 to 30 per cent of recipients.

It is also being designed to have 'inconsequential toxicity' and long-term protection reducing the need for repeated booster immunisations.

"What this means is that there will be no toxicity felt because the does not survive in the vaccinated individual long enough to cause any problems," Prof Mukkur says.

"In addition, the existing vaccine provides relatively short-term protection – three to five years mandating multiple boosters for protection for longer periods.

"Our vaccine is likely to provide a very long-term protection so there may not be a need for a booster.

"If there is [a need, then] certainly not more than one booster, whereas the current vaccine requires nearly seven to eight boosters throughout one's lifetime."

In 2011 there were approximately 38,500 cases of in Australia but an intensive vaccination program reduced the figure to 26,000 in 2012.

Prof Mukkur says this is still too high for a preventable infectious disease.

"Whooping cough is an infection that if passed on to vulnerable babies can be potentially fatal," he says.

"Initially the target population for this will be adults then adolescents and then children.

"Five to nine year-old children and 10 to 14 year-old adolescents are the biggest carriers and potential transmitters of infections to infants so that's where our focus is at present."

add to favorites email to friend print save as pdf

Related Stories

More evidence whooping cough protection wanes

Mar 11, 2013

(HealthDay)—Despite high levels of vaccination, the rate of whooping cough in the United States is at its highest level in decades, and one reason may be that immunity from the vaccine diminishes each year ...

Recommended for you

Research reveals how lymph nodes expand during disease

Oct 22, 2014

Cancer Research UK and UCL scientists have discovered that the same specialised immune cells that patrol the body and spot infections also trigger the expansion of immune organs called lymph nodes, according to a study published ...

Protecting us from our cells

Oct 22, 2014

Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes ...

User comments